{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 41 of 92', 'CR845-CLIN3103', '6.4.9', 'Prior, Concomitant, and Prohibited Medications', '6.4.9.1', 'Prior and Concomitant Medications', 'Prior medications (including vitamins and herbal supplements) are defined as those that', 'the patient has taken any time during the 3 months prior to the first dose of study drug on', 'Day 1 of the Double-blind Treatment Period. Concomitant medications are medications', 'that are taken from after the start of the first dose of study drug on Day 1 of the', 'Double-blind Treatment Period through the end of the Follow-up Period.', 'Use of antipruritic medications during the study will be recorded on an ongoing basis,', 'starting at screening. Patients having a prescription PRN for the use of anti-itch', 'medication will be stratified as using anti-itch medication even if such medications were', 'not reported to be used during the Run-In period. Medications known for potential anti-', 'pruritic effects but used for a different indication (ex. use of gabapentin for pain', 'management) will not be reported as anti-pruritic medications.', 'All prior and concomitant medications, including over-the-counter medications used by', 'patients during this study, are to be recorded in the appropriate page of the eCRF, as', 'applicable.', '6.4.9.2', 'Restricted and Prohibited Medications', 'During the Treatment Period for either the Double-blind Phase or Open-label Extension', 'Phase, the following medications will be restricted or prohibited (Table 1).', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 42 of 92', 'CR845-CLIN3103', 'Table 1.', 'Restricted and Prohibited Medications', 'Drug, Drug Class, or Treatment', 'Restrictions During the Treatment Period', 'Investigational drug (other than the study', 'Not allowed', 'drug)', 'Ultraviolet B treatments', 'Not allowed', 'Naloxone, naltrexone, or mixed', 'Not allowed from the start of dosing of the', 'agonist-antagonists (eg, buprenorphine and', 'Double-blind Treatment Period to the end of', 'nalbuphine)', 'the Open-label Treatment Period, unless', 'needed to treat an adverse event or emergent', 'medical condition acutely.', 'Antihistamines (oral, IV, or topical)', 'Changes to current prescription should be', 'avoided from screening to the end of the', 'Corticosteroids (oral, IV, or topical)', 'Double-blind Treatment Period unless for the', 'treatments', 'acute treatment of an adverse event or', 'Opioids', 'emergent medical condition (in this case,', 'notify the study medical monitor and, as', 'Gabapentin, pregabalin', 'appropriate, report adverse events).', 'No new medication to treat itch should be', 'initiated during the Double-blind Treatment', 'Period.', 'All new concomitant medications or change of frequency and doses of a concomitant', 'medication will be recorded.', '6.5', 'Study Assessments and Procedures', '6.5.1', 'Schedule of Events for the Double-blind Phase', 'Study procedures for the Double-blind Treatment Period are summarized in Table 2.', 'An ICF will need to be signed prior to initiation of the Screening Visit and any procedures', 'that follow.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 43 of 92', 'CR845-CLIN3103', 'Table 2.', 'Schedule of Events: Double-blind Phase', 'Study Procedures', 'Follow-Up', 'Screening Period', 'Period (for', 'patients not', 'participating in', 'Double-blind End', 'Open-label', 'Screening', 'Run-in', 'of Treatmentb/', 'Extension Phase', 'Visit', 'Period', 'Double-blind Treatment Period', 'Early Termination', 'ONLY)', 'Day -28 to', 'Day -7 to', 'Visit Days', 'Day -7', 'Day 1', 'Week 1', 'Weeks 2 to 12', 'Week 13', 'FU Days 1b-10', 'M/Tu', 'W/Th', 'F/Sa', 'M/Tu', 'W/Th', 'F/Sa', '-28 to -7', '-7 to 1', '1', '3', '5', '8', '10', '12', '85', '85 to 95', '15', '17', '19', '22', '24', '26', '29k', '31', '33', '36', '38', '40', '43', '45', '47', '50', '52', '54', '57k', '59', '61', '64', '66', '68', '71k', '73', '75', '78', '80', '82', 'Administrative procedures', 'Informed consent', 'X', 'Inclusion/exclusion criteria', 'X', 'Xc', 'Medical history/Prior Medications (including', 'X', 'Xc', 'Xc', 'antipruritic medications)/Demographics', 'Randomization', 'X', 'Safety and efficacy evaluations', 'Physical examination', 'X', 'Prescription dry body weight', 'X', 'Pre-dialysis 12-lead electrocardiogram', 'Xd', 'Xd', 'Pre-dialysis vital signs', 'X', 'Xe', 'Xe', 'Xe', 'X\u00b2', 'Hematology, serum chemistry (pre-dialysis)8', 'X', 'X', 'X', 'Serum pregnancy (females of childbearing', 'X\u00b0', 'X', 'potential only)', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}